Related Experiment Video
Updated: Sep 28, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
The safety of valproic acid use for patients with hepatitis C infection
Bradford L Felker1, Kevin L Sloan, Jason A Dominitz
1Department of Veteran Affairs Puget Sound Health Care System, MHC/116, 1660 South Columbian Way, Seattle, WA 98108-1597, USA. bradford.felker@med.va.gov
Objective:
Valproic acid is frequently not recommended for patients with hepatic dysfunction. The authors evaluated the association between hepatitis C and alanine aminotransferase (ALT) values during valproic acid treatment.
Method:
ALT changes in 564 individuals beginning valproic acid treatment were examined. Changes among those with positive hepatitis C status were compared with changes among patients with positive hepatitis C status who were taking other psychotropic agents.
Results:
ALT elevations with valproic acid were significantly greater among patients with positive hepatitis C status than those with negative or unknown status. Among patients with positive hepatitis C status, ALT increases did not differ significantly between valproic acid and other medications.
Conclusions:
Use of valproic acid may be possible for some patients with hepatitis C. ALT increases in seropositive patients may be partially related to chronic hepatitis infection. However, ALT levels should be closely monitored in all hepatitis C patients taking valproic acid.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Anticoagulant Drugs: Low-Molecular-Weight Heparins

